Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lenon is a branded generic formulation of levofloxacin, a third-generation fluoroquinolone antibiotic developed and manufactured by Citi Pharma. It acts as a broad-spectrum antibacterial agent by inhibiting bacterial DNA gyrase (topoisomerase II) and DNA topoisomerase IV, which are essential enzymes for bacterial DNA replication, transcription, repair, and recombination. By interfering with these processes, Lenon prevents bacterial cell division and leads to bacterial cell death. It is administered orally and is indicated for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lenon.